Trevi Therapeutics Inc. (TRVI) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Comparing side by side

Since Trevi Therapeutics Inc. (NASDAQ:TRVI) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trevi Therapeutics Inc. 4 0.00 1.95M -1.72 0.00
Citius Pharmaceuticals Inc. 1 0.00 10.68M -0.81 0.00

In table 1 we can see Trevi Therapeutics Inc. and Citius Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 provides us Trevi Therapeutics Inc. and Citius Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Trevi Therapeutics Inc. 53,179,884.37% 0% 0%
Citius Pharmaceuticals Inc. 2,079,034,455.91% -52.4% -46.2%


The Current Ratio of Trevi Therapeutics Inc. is 4 while its Quick Ratio stands at 4. The Current Ratio of rival Citius Pharmaceuticals Inc. is 1 and its Quick Ratio is has 1. Trevi Therapeutics Inc. is better equipped to clear short and long-term obligations than Citius Pharmaceuticals Inc.

Institutional & Insider Ownership

Roughly 47.6% of Trevi Therapeutics Inc. shares are owned by institutional investors while 1.6% of Citius Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 13.9% of Trevi Therapeutics Inc. shares. Competitively, 42.8% are Citius Pharmaceuticals Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Trevi Therapeutics Inc. -0.66% -17.1% 0% 0% 0% -23.83%
Citius Pharmaceuticals Inc. 21.62% 35% 35% 36.36% -49.06% 29.81%

For the past year Trevi Therapeutics Inc. has -23.83% weaker performance while Citius Pharmaceuticals Inc. has 29.81% stronger performance.


Citius Pharmaceuticals Inc. beats Trevi Therapeutics Inc. on 5 of the 9 factors.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.